Rationally engineered Troponin C modulates in vivo cardiac function and performance in health and disease

Nature Communications

Volumn 7, Issue , 2016, Pages

  Shettigar, Vikram ^a   Zhang, Bo ^a,e   Little, Sean C ^b   Salhi, Hussam E ^a   Hansen, Brian J ^a   Li, Ning ^a   Zhang, Jianchao ^a   Roof, Steve R ^c   Ho, Hsiang Ting ^a   Brunello, Lucia ^a   Lerch, Jessica K ^d   Weisleder, Noah ^a   Fedorov, Vadim V ^a   Accornero, Federica ^a   Rafael Fortney, Jill A ^a   Gyorke, Sandor ^a   Janssen, Paul M L ^a   Biesiadecki, Brandon J ^a   Ziolo, Mark T ^a   Davis, Jonathan P ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c QTest Laboratories Inc   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; INOTROPIC AGENT; TROPONIN C; CALCIUM;

BIOENGINEERING; CALCIUM; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DISEASE TREATMENT; PROTEIN; SURVIVAL;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; ENDOTHELIUM CELL; EXERCISE TOLERANCE; FEMALE; FLUORESCENCE IMAGING; GENE THERAPY; HEART EJECTION FRACTION; HEART FIBROBLAST; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART PERFORMANCE; HEART RATE VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRELOAD RECRUITABLE STROKE WORK; PROTEIN ENGINEERING; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SARCOMERE; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; C57BL MOUSE; CALCIUM SIGNALING; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; DIAGNOSTIC IMAGING; ECHOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; GENE VECTOR; GENETICS; HEART CONTRACTION; HEART VENTRICLE; HEART VENTRICLE FUNCTION; HEK293 CELL LINE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; RABBIT;

ANIMALS; CALCIUM; CALCIUM SIGNALING; ELECTROCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; GENETIC THERAPY; GENETIC VECTORS; HEART VENTRICLES; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; OPTICAL IMAGING; PROTEIN ENGINEERING; RABBITS; TROPONIN C; ULTRASONOGRAPHY; VENTRICULAR FUNCTION;

EID: 84959386936     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10794     Document Type: Article

References (55)

1. Lee, J. A. & Allen, D. G. Modulation of Cardiac Calcium Sensitivity: A New Approach to Increasing the Strength of the Heart 347 (Oxford University Press, Inc., 1993).
2. Davis, J. P. & Tikunova, S. B. Ca(2+) exchange with troponin C and cardiac muscle dynamics. Cardiovasc. Res. 77, 619-626 (2008).
3. Hwang, P. M. & Sykes, B. D. Targeting the sarcomere to correct muscle function. Nat. Rev. Drug Discov. 14, 313-328 (2015).
4. Kass, D. A. & Solaro, R. J. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113, 305-315 (2006).
5. Liu, B., Lee, R. S., Biesiadecki, B. J., Tikunova, S. B. & Davis, J. P. Engineered troponin C constructs correct disease-related cardiac myofilament calcium sensitivity. J. Biol. Chem. 287, 20027-20036 (2012).
6. Tikunova, S. B. & Davis, J. P. Designing calcium-sensitizing mutations in the regulatory domain of cardiac troponin C. J. Biol. Chem. 279, 35341-35352 (2004).
7. Feest, E. R. et al. Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts. J. Mol. Cell. Cardiol. 72, 219-227 (2014).
8. Kekenes-Huskey, P. M., Lindert, S. & McCammon, J. A. Molecular basis of calcium-sensitizing and desensitizing mutations of the human cardiac troponin C regulatory domain: a multi-scale simulation study. PLoS Comput. Biol. 8, e1002777 (2012).
9. Norman, C., Rall, J. A., Tikunova, S. B. & Davis, J. P. Modulation of the rate of cardiac muscle contraction by troponin C constructs with various calcium binding affinities. Am. J. Physiol. Heart Circ. Physiol. 293, H2580-H2587 (2007).
10. Tikunova, S. B. et al. Effect of calcium-sensitizing mutations on calcium binding and exchange with troponin C in increasingly complex biochemical systems. Biochemistry 49, 1975-1984 (2010).
11. Wang, D. et al. Structural and functional consequences of the cardiac troponin C L48Q Ca(2+)-sensitizing mutation. Biochemistry 51, 4473-4487 (2012).
12. Luo, M. & Anderson, M. E. Mechanisms of altered Ca(2)(+) handling in heart failure. Circ. Res. 113, 690-708 (2013).
13. Hasenfuss, G. & Teerlink, J. R. Cardiac inotropes: current agents and future directions. Eur. Heart. J. 32, 1838-1845 (2011).
14. Overgaard, C. B. & Dzavik, V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 118, 1047-1056 (2008).
15. Kreutziger, K. L. et al. Calcium binding kinetics of troponin C strongly modulate cooperative activation and tension kinetics in cardiac muscle. J. Mol. Cell. Cardiol. 50, 165-174 (2011).
16. Bar, C. et al. Telomerase expression confers cardioprotection in the adult mouse heart after acute myocardial infarction. Nat. Commun. 5, 5863 (2014).
17. Du, C. K. et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ. Res. 101, 185-194 (2007).
18. McConnell, B. K. et al. Knock-in mice harboring a Ca(2+) desensitizing mutation in cardiac troponin C develop early onset dilated cardiomyopathy. Front. Physiol. 6, 242 (2015).
19. Kirk, J. A. et al. Left ventricular and myocardial function in mice expressing constitutively pseudophosphorylated cardiac troponin I. Circ. Res. 105, 1232-1239 (2009).
20. Murphy, A. M. et al. Transgenic mouse model of stunned myocardium. Science 287, 488-491 (2000).
21. Martins, A. S. et al. In vivo analysis of Troponin C knock-in (A8V) mice: evidence that TNNC1 is a hypertrophic cardiomyopathy susceptibility gene. Circ. Cardiovasc. Genet. 8, 653-664 (2015).
22. Zhang, B., Davis, J. P. & Ziolo, M. T. Cardiac catheterization in mice to measure the pressure volume relationship: investigating the Bowditch effect. J. Vis. Exp. 100, e52618 (2015).
23. Georgakopoulos, D. et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am. J. Physiol. 274, H1416-H1422 (1998).
24. Bers, D. M. & Ziolo, M. T. When is cAMP not cAMP? Effects of compartmentalization. Circ. Res. 89, 373-375 (2001).
25. Ehsani, A. A., Biello, D., Seals, D. R., Austin, M. B. & Schultz, J. The effect of left ventricular systolic function on maximal aerobic exercise capacity in asymptomatic patients with coronary artery disease. Circulation 70, 552-560 (1984).
26. Kaminsky, L. A. & Tuttle, M. S. Functional assessment of heart failure patients. Heart Fail. Clin. 11, 29-36 (2015).
27. Curfman, G. D. Inotropic therapy for heart failure-an unfulfilled promise. N. Engl. J. Med. 325, 1509-1510 (1991).
28. Toma, M. & Starling, R. C. Inotropic therapy for end-stage heart failure patients. Curr. Treat. Options Cardiovasc. Med. 12, 409-419 (2010).
29. Kobayashi, T. & Solaro, R. J. Calcium, thin filaments, and the integrative biology of cardiac contractility. Annu. Rev. Physiol. 67, 39-67 (2005).
30. Biesiadecki, B. J., Davis, J. P., Ziolo, M. T. & Janssen, P. M. Tri-modal regulation of cardiac muscle relaxation; intracellular calcium decline, thin filament deactivation, and cross-bridge cycling kinetics. Biophys. Rev. 6, 273-289 (2014).
31. Loughran, J. H., Chugh, A. R., Ismail, I. & Bolli, R. Stem cell therapy: promising treatment in heart failure? Curr. Heart Fail. Rep. 10, 73-80 (2013).
32. Heusch, G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381, 166-175 (2013).
33. Bussmann, W.-D. Acute and Chronic Heart Failure: Diagnosis and Therapy 286 (Springer-Verlag, 1986).
34. Feldman, D. S., Elton, T. S., Sun, B., Martin, M. M. & Ziolo, M. T. Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat. Clin. Pract. Cardiovasc. Med. 5, 208-218 (2008).
35. Bonne, G., Carrier, L., Richard, P., Hainque, B. & Schwartz, K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ. Res. 83, 580-593 (1998).
36. Greenberg, B. et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail. 2, 84-92 (2014).
37. Little, S. C. et al. The rates of Ca2+ dissociation and cross-bridge detachment from ventricular myofibrils as reported by a fluorescent cardiac troponin C. J. Biol. Chem. 287, 27930-27940 (2012).
38. Johnson, P. R. et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15, 901-906 (2009).
39. Glukhov, A. V. et al. Calsequestrin 2 deletion causes sinoatrial node dysfunction and atrial arrhythmias associated with altered sarcoplasmic reticulum calcium cycling and degenerative fibrosis within the mouse atrial pacemaker complex1. Eur. Heart J. 36, 686-697 (2015).
40. Lou, Q. et al. Upregulation of adenosine A1 receptors facilitates sinoatrial node dysfunction in chronic canine heart failure by exacerbating nodal conduction abnormalities revealed by novel dual-sided intramural optical mapping. Circulation 130, 315-324 (2014).
41. Hansson, G. K. & Schwartz, S. M. Evidence for cell death in the vascular endothelium in vivo and in vitro. Am. J. Pathol. 112, 278-286 (1983).
42. Ohno, M. et al. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with In situ nick end-labeling. Circulation 98, 1422-1430 (1998).
43. Janssen, P. M. et al. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy. PLoS ONE 9, e88360 (2014).
44. Rafael-Fortney, J. A. et al. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 124, 582-588 (2011).
45. Dumont, E. A. et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation 102, 1564-1568 (2000).
46. Kabaeva, Z., Meekhof, K. E. & Michele, D. E. Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function. Hum. Mol. Genet. 20, 3346-3355 (2011).
47. Pusztaszeri, M. P., Seelentag, W. & Bosman, F. T. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J. Histochem. Cytochem. 54, 385-395 (2006).
48. Hermiston, M. L., Xu, Z. & Weiss, A. CD45: a critical regulator of signaling thresholds in immune cells. Annu. Rev. Immunol. 21, 107-137 (2003).
49. Biesiadecki, B. J. et al. Removal of the cardiac troponin I N-terminal extension improves cardiac function in aged mice. J. Biol. Chem. 285, 19688-19698 (2010).
50. Nixon, B. R. et al. Combined troponin I Ser-150 and Ser-23/24 phosphorylation sustains thin filament Ca(2+) sensitivity and accelerates deactivation in an acidic environment. J. Mol. Cell. Cardiol. 72, 177-185 (2014).
51. Rhyner, J. A., Koller, M., Durussel-Gerber, I., Cox, J. A. & Strehler, E. E. Characterization of the human calmodulin-like protein expressed in Escherichia coli. Biochemistry 31, 12826-12832 (1992).
52. Kohr, M. J. et al. Biphasic effect of SIN-1 is reliant upon cardiomyocyte contractile state. Free Radic. Biol. Med. 45, 73-80 (2008).
53. Accornero, F. et al. Genetic analysis of connective tissue growth factor as an effector of transforming growth factor beta signaling and cardiac remodeling. Mol. Cell. Biol. 35, 2154-2164 (2015).
54. Roof, S. R. et al. Obligatory role of neuronal nitric oxide synthase in the heart's antioxidant adaptation with exercise. J. Mol. Cell. Cardiol. 81, 54-61 (2015).
55. Makara, M. A. et al. Ankyrin-G coordinates intercalated disc signaling platform to regulate cardiac excitability in vivo. Circ. Res. 115, 929-938 (2014).